Sofosbuvir - Gilead Sciences

Drug Profile

Sofosbuvir - Gilead Sciences

Alternative Names: GS-7977; HEPCINAT; Hepcvir; P-7977; PSI-7977; Sovaldi; SoviHep

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmasset
  • Developer Bristol-Myers Squibb; Gilead Sciences; Hannover Medical School
  • Class Antivirals; Phosphoric acid esters; Pyrimidine nucleotides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C
  • Phase II Hepatitis E

Most Recent Events

  • 01 Dec 2017 Phase-II clinical trials in Hepatitis E in Germany (PO) (NCT03282474) (EudraCT2017-000403-24)
  • 19 Oct 2017 Gilead Sciences completes a phase IIb trial for Hepatitis C (Combination therapy, in patients with renal insufficiency) in USA, Germany, Austria, New Zealand, Netherlands and Puerto Rico (PO) (NCT01958281)
  • 25 Sep 2017 Registered for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced, In adolescents, In adults) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top